SELLAS Life Sciences Group, Inc. Cash Provided by (Used in) Operating Activities, Discontinued Operations
SELLAS Life Sciences Group, Inc. (SLS) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of -$9.94 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2017-09-30 was -$2.45M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2017-06-30 was -$2.48M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2017-03-31 was -$5.00M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2016-12-31 was -$2.53M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2016 was -$11.69M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2015 was -$9.36M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2014 was -$5.83M.
- SELLAS Life Sciences Group, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2013 was -$5.65M.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$4.93M derived: sum of 2 quarters · filed 2017-11-09 | -$9.94M 10-Q · filed 2017-11-09 | -$12.47M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | -$2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$7.49M 10-Q · filed 2017-08-14 | -$10.02M derived: sum of 3 quarters · filed 2017-08-14 | -$12.05M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-03-31 | -$5.00M 10-Q · filed 2017-05-10 | -$7.53M derived: sum of 2 quarters · filed 2017-05-10 | -$9.57M derived: sum of 3 quarters · filed 2017-11-09 | -$13.21M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$4.57M derived: sum of 2 quarters · filed 2017-11-09 | -$8.21M derived: sum of 3 quarters · filed 2017-11-09 | -$11.69M 10-K · filed 2017-03-15 |
| 2016-09-30 | -$2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$5.68M derived: sum of 2 quarters · filed 2017-11-09 | -$9.15M 10-Q · filed 2017-11-09 | -$13.47M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | -$3.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$7.12M 10-Q · filed 2017-08-14 | -$11.43M derived: sum of 3 quarters · filed 2017-08-14 | -$12.50M derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | -$3.48M 10-Q · filed 2017-05-10 | -$7.79M derived: sum of 2 quarters · filed 2017-05-10 | -$8.85M derived: sum of 3 quarters · filed 2017-05-10 | -$11.77M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$5.38M derived: sum of 2 quarters · filed 2017-03-15 | -$8.30M derived: sum of 3 quarters · filed 2017-03-15 | -$9.36M 10-K · filed 2017-03-15 |
| 2015-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$3.99M derived: sum of 2 quarters · filed 2016-11-09 | -$5.05M 10-Q · filed 2016-11-09 | -$7.49M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$3.98M 10-Q · filed 2016-08-09 | -$6.42M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$1.06M 10-Q · filed 2016-05-10 | -$3.50M derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$5.83M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$3.39M 10-Q · filed 2015-11-09 | |||
| 2013-12-31 | -$5.65M 10-K/A · filed 2016-04-15 | |||
| 2012-12-31 | -$1.64M 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |